Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > COLUMN
COLUMN
- Rare Diseases in Japan: Moving from Treatment to Integrated Care
October 27, 2022
- The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
- Fairness, Not Diversity
August 26, 2022
- Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
August 5, 2022
- The Winning Combination: Drive, Passion, and Commitment
July 22, 2022
- Please Come Back to the Office!
June 24, 2022
- Customer Engagement in the COVID-Endemic New Normal
June 17, 2022
- Tapping into One’s Ikigai by Working from Home
May 27, 2022
- The Road to Success Is Paved with the Stepping-Stones of Disappointment
April 22, 2022
- Five Ways to Get Your New Hire on the Same Page
March 31, 2022
- 4 Things You Can Do to Overcome Zoom Overload
November 26, 2021
- What Does a Great Boss Look Like?
October 29, 2021
- What Is the Price of a Work-Life Balance?
September 24, 2021
- Obituary: P. Reed Maurer
September 14, 2021
- Digital and Cultural Transformation in Japanese Pharmaceuticals
August 13, 2021
- How Manufacturers Can Optimize Wholesaler Relationships and Leverage Wholesalers to Support Business Strategy
July 13, 2021
- Does Your Company Want to Increase Its Diversity?
July 5, 2021
- 5 Lessons in 5 Years from Rocking the Bag
June 17, 2021
- Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
May 28, 2021
- Set the Stage for an Exceptional Customer Experience
May 21, 2021
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…